Ingalls & Snyder’s Eupraxia Pharmaceuticals EPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRX
Ingalls & Snyder's EPRX Position: Q3 2026 in Review
Ingalls & Snyder increased its Eupraxia Pharmaceuticals (EPRX) stake by 10% in Q3 2026, buying an estimated $49.8K and bringing the position to 75,450 shares worth $687K. The position accounts for 0.02% of the portfolio, ranked #255.
Ingalls & Snyder first reported a position in EPRX in Q2 2025 and has held it in 6 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.
- Ingalls & Snyder held 75,450 shares of Eupraxia Pharmaceuticals worth $687K as of Q3 2026.
- Ingalls & Snyder bought 7,000 Eupraxia Pharmaceuticals shares in Q3 2026, an estimated $49.8K.
- Eupraxia Pharmaceuticals made up 0.02% of Ingalls & Snyder's portfolio in Q3 2026, its #255 holding.
- Ingalls & Snyder first reported a position in Eupraxia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
- 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.
Based on Ingalls & Snyder's 13F filing for Q3 2026, filed 12 Nov 2026.